ROCKVILLE, MD , Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's

ROCKVILLE, MD , Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Strengthened financial position resulting from recently announced MARGENZA ® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ ® ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call

Scott Koenig , M.D., Ph.D., to step down as President and CEO Board to initiate search process to identify new CEO ROCKVILLE, MD , Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing

ROCKVILLE, MD , Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, Md. & DEERFIELD, Ill. --(BUSINESS WIRE)--Oct. 22, 2024-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC ,

Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohort Company

MacroGenics to host investor call to review key data presented at ESMO on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD , Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and

Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in September Received $100.0 million in milestones related to Incyte’s advancement of ZYNYZ ® (retifanlimab-dlwr ) subsequent to quarter-end Confirming cash runway guidance into 2026 ROCKVILLE, Md. , Aug.

Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in September ESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safety Treatment recently discontinued for

Confirming cash runway guidance into 2026 ROCKVILLE, MD , July 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today

ROCKVILLE, MD , June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on

ROCKVILLE, MD , May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study,   as submitted in ASCO abstract Company plans to provide updated interim data, including safety and preliminary efficacy, by May 31 Company plans to provide additional clinical

Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC Preclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and

ROCKVILLE, MD , March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , Feb. 02, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Jan. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md. , Nov.

ROCKVILLE, MD , Nov. 02, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will

ROCKVILLE, MD , Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

ROCKVILLE, MD , Sept. 05, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc.